ACTIVATION OF THE UNFOLDED PROTEIN RESPONSE IN GAUCHER DISEASE Gali Maor and Mia Horowitz EWGGD, Paris June 27-30, 2012 Gaucher Disease Due to the defective activity of lysosomal glucocerebrosidase (GCase) in Gaucher disease there is: ★Accumulation of substrate ★ERAD of mutant GCase variants EP Gaucher ERAD of mutant GCase variants ERAD has been shown for the following genotypes (mutations): N370S/N370S, N370S/L444P, N370S/V394, N370S/recTl, N370S/V394L, R120W/R120W, L444P/R120W, G202R/G202R+M362I, L444P/P415R, G202R/G202R, K157Q/D140H+E326K, R463C/?, R131C/R131C, L444P/L444P, L444P/R415P, D409H/D409H Every ER resident or passenger protein undergoes ERQC and, if needed, ERAD!!! Quantitation of ERAD TOTAL AMOUNT (% OF NORMAL) A AMOUNT IN LYSOSOMES (% OF A) B N370S/N370S 47.3 79.8 37.7 N370S/N370S 70.6 89.8 63.4 N370S/N370S 49.8 84.9 42.2 N370S/V394L 45.2 27.2 12.2 R463C/? 31.9 63.9 20.4 TYPE 3 14.8 34.5 4.9 TYPE2 15.5 4.1 0.6 P415R/L444P 20.3 1.9 0.4 WT 100 89.8 89.8 ERAD GENOYYPE AXB There is a correlation between the severity of the disease and the ERAD level ERAD of mutant GCase variants ERAD of mutant GCase variants may lead to pathogenesis The Unfolded Protein Response 1 3 Douglas M. Cyr & Daniel N. Hebert, Embo Reports April 2012 2 1 (CHOP) Test UPR by : 1.Changes in mRNA and protein levels of Bip, CHOP 2.Phosphorylation of eIF2α 3.Splicing of Xbp1 mRNA Gaucher Disease CUPR exists in GD derived cells CUPR also exists in carriers of GD mutations CUPR upregulates GBA transcription Relative mRNA quantity UPR in GD patients and carriers: Bip and CHOP mRNA levels 12 CHOP 10 BiP ** P < 0.01 ** * 8 ** * ** ** ** * P < 0.05 * * 6 4 * * ** 3 4 * * 2 0 1 2 5 6 Patient Number 7 8 9 Patient number Genotype Disease type Relative Chop mRNA Relative BiP mRNA 1 WT - 1 1 2 N370S/N370S 1 5.5±2.6* 6.2±3.1** 3 L444P/R120W 2 2.8±1.4* 4.2±0.6* 4 G202R/G202R+M362I 2 3.3±1.6* 3±1.7* 5 L444P/L415W 2 8.9±2.1** 6±2* 6 G202R/G202R 2 8.7±3.1** 8.5±4* 7 K157Q/D140H+E326K 1 (severe) 4.3±2.19 * 3.6±1.48 * 8 K157Q/D140H+E326K 1 9.2±2.94 ** 7.2±2.87** 9 N370S/N370S 1 (severe) 4.1 3.4 ±1.82* BiP Relative protein quantity UPR in GD patients: Bip and CHOP proteins 4 3,5 3 2,5 2 1,5 1 0,5 0 * * ** P < 0.01 β-tubulin * P < 0.05 Relative protein quantity Genotype 12 10 8 6 4 2 0 ** * ** * CHOP β-tubulin Gnotype Bip and CHOP mRNA and protein levels are significantly elevated in GD fibroblasts UPR in GD patients: Xbp1 splicing Forward primer Reverse primer No splicing Splicing Forward primer Reverse primer Forward primer Reverse primer Spliced xbp1 mRNA quantity 1,2 1 ** * 0,8 0,6 ** 0,4 0,2 0 GAPDH Level of Xbp1 splicing is significantly elevated in GD fibroblasts Genotype * P-EIF2α EIF2α Relative protein quantity UPR in GD patients: Phosphorylation of eIF2α 5 4,5 4 3,5 3 2,5 2 1,5 1 0,5 0 ** ** Genotype * P < 0.01 ** P < 0.05 Levels of phosphorylated eIF2α protein are significantly elevated in GD fibroblasts Unfolded Protein Response in GD Relative mRNA quantity (%) Relative GCase activity (%) 6 120 100 80 60 40 20 0 0 1 CBE treatment (days) 10 5 * * P < 0.05 CHOP * BiP 4 3 2 1 0 WT WT+CBE WT+Tg Patient Disease type Relative Chop mRNA Relative BiP mRNA WT - 1 1 WT+CBE treatment - 0.82±0.24 0.86±0.41 WT+Tg treatment - 5.04±0.42* 3.9±1.28* Substrate accumulation does not lead to UPR UPR in GD mice (Grabowski): Bip and CHOP proteins A 4,5 Relative mRNA quantity 4 3,5 * P < 0.05 CHOP BiP Genotype Relative Chop mRNA Relative BiP mRNA WT 1 1 2 D409H/D409H 0.155±0.04 0.69±0.08 1,5 D409V/D409V *2.7±0.5 *2.02±0.4 KO 0.7±0.06 1.08±0.3 WT+Tg *3.81 *2.91 * 3 * 2,5 1 0,5 0 WT D409H/D409H D409V/D409V KO Thapsigargin Genotype Bip and CHOP mRNA levels are significantly elevated only in D409V homozygous mice!!! UPR in GD mice: Xbp1 splicing A Forward primer Reverse primer No splicing Splicing Forward primer Relative mRNA quantity Reverse primer Forward primer Reverse primer 3,5 3 * * P < 0.05 2,5 * 2 1,5 1 0,5 0 Genotype Level of Xbp1 splicing is significantly elevated in D409V homozygous mouse fibroblasts Gaucher Disease CUPR exists in GD derived cells CUPR also exists in carriers of GD mutations CUPR upregulates GBA transcription Gaucher Disease CUPR exists in GD derived cells CUPR also exists in carriers of GD mutations CUPR upregulates GBA transcription Gaucher Disease CUPR exists in GD derived cells CUPR also exists in carriers of GD mutations CUPR upregulates GBA transcription Unfolded Protein Response in GD carriers 8 CHOP 7 BiP * 6 5 4 3 2 1 4 Relative spliced Xbp1 mRNA quantity Relative mRNA quantity 9 3,5 3 **P < 0.01 ** * P < 0.05 ** 2,5 2 1,5 1 0,5 0 0 Normal WT/N370S Genotype WT/84GG Normal WT/84GG Genotype WT/N370S There is UPR in GD carriers even without a detected protein Gaucher Disease CUPR exists in GD derived cells CUPR also exists in carriers of GD mutations CUPR upregulates GBA transcription GBA mRNA levels in GD fibroblasts ** There are elevated levels of GBA mRNA in GD derived fibroblasts Does it result from response to UPR?????? GBA mRNA levels in GD fibroblasts ** Relative GCase mRNA expression 9 8 7 6 * P < 0.05 ** ** * * * * 5 4 3 * 2 1 0 Genotype Genotype Disease type Relative mRNA quantity WT - 1 N370S/N370S 1 *4.4±1.2 L444P/R120W 2 3.3±1.7 R131C/R131C 2 3±1.1 L444P/L444P 3 5.1±1.3* N370S/WT - *5.7±0.8 WT+CBE - 0.99±0.43 84GG/WT - 1.7±0.1* N370S/WT - 5.3±2.3* There are elevated levels of GBA mRNA in GD derived and carrier derived fibroblasts GBA mRNA levels in GD fibroblasts ** In UPR there are genes that are upregulated by the transcription factor CHOP. Does the GBA gene promoter have a UPR Responsive element? GBA mRNA levels in GD fibroblasts CHOP -350 AP-1 PEA +1 CAAT GBA Vector delivery to living cells Luciferase in HEK293 cells 1,6 No Thapsigargin * P < 0.01 * 1,4 Thapsigargin Luminscence 1,2 1 0,8 0,6 0,4 0,2 0 CAAT mut Normal Upon UPR induction (with thapsigargin) normal (but not CAAT mutated) GBA promoter activity elevates. GBA promoter binds CHOP Gaucher Disease Since UPR in general may lead to cell death, UPR in GD may lead to death of cells as well. Dopaminergic cells (Parkinson disease)?! Conclusions There is UPR in GD patients There is UPR in one animal models (out of few we have tested) There is UPR in GD carriers including the 84GG carriers There is upregulation of the GBA gene in patients in response to UPR, through CHOP binding Even without ERAD there is UPR (ER stress) that may lead to death of cells for example in the case of 84GG carriers and PD ERAD of mutant GCase variants Gaucher disease (mutant GCase) Parkinson disease ERAD of mutant GCase variants may lead to pathogenesis Thanks Collaborator: Dr. M. Filocamo Gali Maor Thank you for your attention